The Phase III KOASTAL-1 study with Neumora’s lead asset navacaprant failed to meet its primary and secondary endpoint.

Drug manufacturers increased the list prices of at least 250 brand-name medications as of Jan. 1 as the future of the ...

States are channeling funds into overdose response equipment, drug identification tools and community recovery initiatives ...

The Royal Society of Chemistry’s (RSC’s) immediate past president, Gill Reid, is one of several members of the chemical ...

Barring Sun Pharma, which declined 0.6 per cent, the rest of the 29 shares in the 30-share Sensex ended higher ...

Star RMG Infrastructure Limited, established in 2001, continues to lead the infrastructure sector with cutting-edge projects ...

Markets staged a robust comeback in the first trading session of 2024, with the benchmark Sensex surging 1,436.30 points ...

Veeda Group has unveiled a new logo and brand identity--Veeda Lifesciences--marking a key milestone in its journey. The new ...

The Role of Water for Injection (WFI) in Pharmaceutical ManufacturingWater for Injection (WFI) serves as a cornerstone of ...

Louisville basketball guard Spencer Legg is living with type 1 diabetes. Here's how he's using his diagnosis to raise ...

Korean contract development and manufacturing organizations (CDMOs) are set to engage with global drugmakers at the upcoming ...

Japan Airlines (JAL) is taking a significant leap forward in the logistics and healthcare sectors by incorporating drone ...